Tuberculosis treatment in HIV infected ugandans with CD4 counts >350 cells/mm3 reduces immune activation with no effect on HIV load or CD4 count

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Mahan, C Scott ^a,b   Walusimbi, Maria ^c   Johnson, Denise F ^a   Lancioni, Christina ^a   Charlebois, Edwin ^d   Baseke, Joyce ^c   Chervenak, Keith A ^a   Mugerwa, Roy D ^c   Havlir, Diane V ^d   Mayanja Kizza, Harriet ^c   Whalen, Christopher C ^e   Boom, W Henry ^a,f  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF GEORGIA   (United States)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ETHAMBUTOL; HLA DR ANTIGEN; ISONIAZID; MARKER; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MALE; MIXED INFECTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMEAR; UGANDA; VIRUS LOAD; ADULT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MIDDLE AGED; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; ETHAMBUTOL; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS; UGANDA; VIRAL LOAD; YOUNG ADULT;

EID: 77949590071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009138     Document Type: Article

References (16)

1. Lawn SD, Butera ST, Folks TM (2001) Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 14: 753-777.
2. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, et al. (1998) The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 178: 1642-1648.
3. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, et al. (1996) Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 157: 1271-1278.
4. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, et al. (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. Aids 16: 75-83.
5. Kalou M, Sassan-Morokro M, Abouya L, Bile C, Maurice C, et al. (2005) Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire. J Med Virol 75: 202-208.
6. Morris L, Martin DJ, Bredell H, Nyoka SN, Sacks L, et al. (2003) Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis 187: 1967-1971.
7. Lawn SD, Shattock RJ, Acheampong JW, Lal RB, Folks TM, et al. (1999) Sustained plasma TNF-alpha and HIV-1 load despite resolution of other parameters of immune activation during treatment of tuberculosis in Africans. Aids 13: 2231-2237.
8. Jones BE, Oo MM, Taikwel EK, Qian D, Kumar A, et al. (1997) CD4 cell counts in human immunodeficiency virus-negative patients with tuberculosis. Clin Infect Dis 24: 988-91.
9. Fahey JL, Taylor JM, Detels R, Hofmann B, Melmed R, et al. (1990) The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 322: 166-172.
10. Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, et al. (2000) Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. Aids 14: 1219-1228.
11. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ (2006) Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 12: 289-295.
12. Toossi Z (2003) Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 188: 1146-1155.
13. Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, et al. (2000) T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol 122: 350-357.
14. Srikantiah P, Wong JK, Liegler T, Walusimbi M, Mayanja-Kizza H, et al. (2008) Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis. J Acquir Immune Defic Syndr 49: 458-460.
15. Goletti D, Carrara S, Vincenti D, Giacomini E, Fattorinia L, et al. (2004) Inhibition of HIV-1 replication in monocyte-derived macrophages by Mycobacterium tuberculosis. J Infect Dis 189: 624-633.
16. Villacian J, Tan GB, Teo LF, Paton N (2005) The effect of infection with Mycobacterium tuberculosis on T-cell activation and proliferation in patients with and without HIV co-infection. J of Infect 51: 408-412.